Importance In clinical practice, patients with primary metastatic renal cell carcinoma (mRCC)
have been offered cytoreductive nephrectomy (CN) followed by targeted therapy, but the …

Background The use of cytoreductive nephrectomy (CN) selectively for patients who show a
favorable response to upfront systemic therapy may be an approach to select optimal …

Background Cytoreductive nephrectomy has been the standard of care in metastatic renal-
cell carcinoma for 20 years, supported by randomized trials and large, retrospective studies …

Background The CARMENA trial in patients with metastatic renal cell carcinoma (mRCC)
demonstrated that treatment with sunitinib alone was noninferior to cytoreductive …

BACKGROUND: The role of cytoreductive nephrectomy in metastatic clear cell renal cell
carcinoma (ccRCC) is controversial. OBJECTIVE: To determine the outcome of patients with …

Context The current role of cytoreductive nephrectomy (CN) is controversial. Objective
Review of the available evidence about criteria defining CN optimal candidates. Evidence …

Background The benefit of cytoreductive nephrectomy (CN) for overall survival (OS) is
unclear in patients with synchronous metastatic renal cell carcinoma (mRCC) in the era of …

4508 Background: Carmena was a randomized phase III trial, testing the benefit of CN
followed by sunitinib (arm A) vs sunitinib alone (arm B), with stratification by MSKCC risk …

Context The role of cytoreductive nephrectomy (CN) in the management of metastatic renal
cell carcinoma (mRCC) in the targeted therapy (TT) era is controversial. Objective To assess …

Background The safety and efficacy of upfront sunitinib, before nephrectomy in metastatic
clear cell renal cancer (mCRC), has not been prospectively evaluated. Methods Two …